Compare AIXC & GRDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIXC | GRDX |
|---|---|---|
| Founded | 1996 | N/A |
| Country | United States | United Kingdom |
| Employees | 10 | 2 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.9M | 28.6M |
| IPO Year | N/A | N/A |
| Metric | AIXC | GRDX |
|---|---|---|
| Price | $1.29 | $6.22 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 41.4K | ★ 164.3K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.92 | $1.87 |
| 52 Week High | $2.98 | $6.93 |
| Indicator | AIXC | GRDX |
|---|---|---|
| Relative Strength Index (RSI) | 48.57 | 71.45 |
| Support Level | $1.18 | $2.16 |
| Resistance Level | $1.48 | $6.93 |
| Average True Range (ATR) | 0.10 | 0.64 |
| MACD | -0.00 | 0.11 |
| Stochastic Oscillator | 38.71 | 78.03 |
AIxCrypto Holdings Inc is a technology infrastructure company focused on the convergence of artificial intelligence and blockchain-based programmable systems. The Company develops software platforms and programmable infrastructure designed to facilitate the tokenization of real-world assets (RWA) and the deployment of Embodied Artificial Intelligence (EAI) in commercial environments. Its mission is to serve as the regulated, programmable infrastructure layer connecting traditional capital markets with on-chain systems and AI-enabled commercial systems.
GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.